These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22264479)

  • 1. Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.
    Ramurthy S; Costales A; Jansen JM; Levine B; Renhowe PA; Shafer CM; Subramanian S
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1678-81. PubMed ID: 22264479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.
    Ramurthy S; Aikawa M; Amiri P; Costales A; Hashash A; Jansen JM; Lin S; Ma S; Renhowe PA; Shafer CM; Subramanian S; Sung L; Verhagen J
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3286-9. PubMed ID: 21543226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.
    Ashton KS; St Jean DJ; Poon SF; Lee MR; Allen JG; Zhang S; Lofgren JA; Zhang X; Fotsch C; Hungate R
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5191-6. PubMed ID: 21824779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of novel benzoheterocyclic derivatives as human acrosin inhibitors by scaffold hopping.
    Chen Q; Tian W; Han G; Qi J; Zheng C; Zhou Y; Ding L; Zhao J; Zhu J; Lv J; Sheng C
    Eur J Med Chem; 2013 Jan; 59():176-82. PubMed ID: 23220646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IRAK-4 inhibitors. Part 1: a series of amides.
    Buckley GM; Gowers L; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V; Fraser JL
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3211-4. PubMed ID: 18474425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators.
    Pettersson M; Johnson DS; Subramanyam C; Bales KR; am Ende CW; Fish BA; Green ME; Kauffman GW; Lira R; Mullins PB; Navaratnam T; Sakya SM; Stiff CM; Tran TP; Vetelino BC; Xie L; Zhang L; Pustilnik LR; Wood KM; O'Donnell CJ
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2906-11. PubMed ID: 22429469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.
    Tully DC; Liu H; Alper PB; Chatterjee AK; Epple R; Roberts MJ; Williams JA; Nguyen KT; Woodmansee DH; Tumanut C; Li J; Spraggon G; Chang J; Tuntland T; Harris JL; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1975-80. PubMed ID: 16446091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors.
    Wang X; Salaski EJ; Berger DM; Powell D; Hu Y; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6941-4. PubMed ID: 22024030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
    Wilson KJ; Illig CR; Chen J; Wall MJ; Ballentine SK; DesJarlais RL; Chen Y; Schubert C; Donatelli R; Petrounia I; Crysler CS; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Meegalla SK
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3925-9. PubMed ID: 20570147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel bis-aromatic amides as novel PTP1B inhibitors.
    Wang WL; Huang C; Gao LX; Tang CL; Wang JQ; Wu MC; Sheng L; Chen HJ; Nan FJ; Li JY; Li J; Feng B
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1889-94. PubMed ID: 24684845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors.
    Wu Z; Yang C; Graham TH; Verras A; Chabin RM; Xu S; Tong X; Xie D; Lassman ME; Bhatt UR; Garcia-Calvo MM; Shen Z; Chen Q; Bleasby K; Sinharoy R; Hale JJ; Tata JR; Pinto S; Colletti SL; Shen DM
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1727-30. PubMed ID: 22290078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of heterocycle containing adamantane 11beta-HSD1 inhibitors.
    Yeh VS; Patel JR; Yong H; Kurukulasuriya R; Fung S; Monzon K; Chiou W; Wang J; Stolarik D; Imade H; Beno D; Brune M; Jacobson P; Sham H; Link JT
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5414-9. PubMed ID: 16899366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
    J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
    Kim MH; Kim M; Yu H; Kim H; Yoo KH; Sim T; Hah JM
    Bioorg Med Chem; 2011 Mar; 19(6):1915-23. PubMed ID: 21353571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.
    Scheiper B; Matter H; Steinhagen H; Böcskei Z; Fleury V; McCort G
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5480-6. PubMed ID: 21840218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.
    Barta TE; Becker DP; Bedell LJ; Easton AM; Hockerman SL; Kiefer J; Munie GE; Mathis KJ; Li MH; Rico JG; Villamil CI; Williams JM
    Bioorg Med Chem Lett; 2011 May; 21(10):2820-2. PubMed ID: 21507637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.
    Wang L; Hubert JA; Lee SJ; Pan J; Qian S; Reitman ML; Strack AM; Weingarth DT; MacNeil DJ; Weber AE; Edmondson SD
    Bioorg Med Chem Lett; 2011 May; 21(10):2911-5. PubMed ID: 21493064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition metal free hydrolysis/cyclization strategy in a single pot: synthesis of fused furo N-heterocycles of pharmacological interest.
    Nakhi A; Rahman MS; Seerapu GP; Banote RK; Kumar KL; Kulkarni P; Haldar D; Pal M
    Org Biomol Chem; 2013 Aug; 11(30):4930-4. PubMed ID: 23824158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.